Predictors of long-term remission following trans-sphenoidal surgery in cushing's disease: a systematic review and meta-analysis based on different remission criteria.

Cushing's Disease (CD) is caused by pituitary adenomas, leading to hypercortisolism. This condition burdens patients socioeconomically, with a reduced quality of life and higher mortality. Transsphenoidal surgery (TSS) is the first-line treatment, offering a 78% remission rate. This study aims to identify factors influencing TSS outcomes to find the predictors of remission for improved treatment planning. A systematic search of electronic databases was performed based on the PRISMA guideline. Studies were selected if they reported data on remission and non-remission groups. A comparative meta-analysis was performed based on the variable type. This review included 11,666 patients treated with TSS for CD, with a remission rate of 73.88%. The mean age was 39.1 years, predominantly female (75.21%), with an average follow-up of 53.29 months. Remission rates were higher in patients with positive MRI results (78.47% vs. 66.11%, P < 0.01), microadenomas (79.16% vs. 64.70%, P < 0.01), without cavernous sinus invasion (78.50% vs. 47.54%, P < 0.01), first-time TSS (81.98% vs. 63.80%, P < 0.01), selective adenectomy surgery (81.24% vs. 64.54%, P < 0.01), and positive adenoma pathology (80.37% vs.54.65%, P < 0.01). Patients who achieved long-term remission exhibited significantly lower immediate post-operative serum cortisol, Adrenocorticotrophic Hormone (ACTH), and urinary-free cortisol (UFC) levels. The risk of bias was low across most studies. Our systematic review and meta-analysis demonstrate MRI findings, histopathology, tumor size, post-operative cortisol, ACTH, UFC, tumor invasion, and repetition of surgery as predictors of remission. These factors should be considered in patient selection for TSS to maximize clinical benefits.
Cancer
Access
Care/Management

Authors

Maroufi Maroufi, Maroufi Maroufi, Sabahi Sabahi, Borghei-Razavi Borghei-Razavi, Esteghamati Esteghamati
View on Pubmed
Share
Facebook
X (Twitter)
Bluesky
Linkedin
Copy to clipboard